Abstract 2134P
Background
Hodgkin’s lymphoma survivors (HLSs) are at risk for late effects due to their early age at diagnosis, multimodal therapy and long life expectancy. Among HLSs, we explored self-reported late effects, and assessed their information needs regarding lifestyle (diet and physical activity) and rehabilitation, in addition to need for long-term follow-up and factors associated with these needs.
Methods
HLSs treated 1997-2006 and aged 18-49 years at diagnosis were identified by the Norwegian Cancer Registry and invited to participate in this population-based, cross-sectional study consisting of a questionnaire, blood tests, clinical examination and echocardiography. Information regarding histology, stage and treatment was retrieved from medical records. Descriptive statistics and logistic regression models were used.
Results
Among the participants (n=304, 59% response rate), median age at diagnosis was 29 years (range 8-49), median age at survey 45 years (21-70), median observation time 16 years (10-22) and 48 % were females. Ninety percent had classical HL, 62% had stage I-IIA disease, 94% received chemotherapy and 77% radiotherapy. Seventy-four percent reported to have experienced ≥1 late effects; concentration/memory problems (29%), numbness/nerve pain (32%) and dental problems (27%) were the most common. Forty-one percent reported chronic fatigue (CF). One third reported to have received follow-up for late effects. A total of 64% wanted information about lifestyle and/or rehabilitation, and 58% wanted regularly follow-up for late effects. In the multivariable models, CF (OR 2.2, 95%CI 1.2-4.1), short education (2.2, 1.2-4.0), being physical inactive (2.0, 1.1-3.5) were associated with increased likelihood of need for information about lifestyle and/or rehabilitation. CF was associated with increased likelihood of need for follow-up for late effects (2.1, 1.3-3.6).
Conclusions
HLSs report a high level of late effects and only a small proportion receive follow-up for these problems. Chronic fatigue is associated with need for information and follow-up, indicating that these patients could benefit from a more structured model for long-term follow-up than what is currently available.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Oslo University Hospital.
Funding
Norwegian Cancer Society and the DAM foundation, project number 2019/FO247426; Norwegian Extra Foundation for Health and Rehabilitation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2184TiP - Extensive cardiovascular characterization and follow-up of patients receiving immune checkpoint inhibitors: A prospective multicenter study
Presenter: Danielle Delombaerde
Session: Poster session 07
2185TiP - Belgian FORX trial: FOod interventions to Reduce immunotherapy toXicity
Presenter: Marthe Verhaert
Session: Poster session 07
2186P - KN046 in patients with thymic carcinoma: A prospective, single-arm, multi-centre, phase II study
Presenter: Wentao Fang
Session: Poster session 07
2187P - Efficacy and safety of gemcitabine as maintenance treatment in unresectable malignant pleural mesothelioma: A phase II randomized study
Presenter: Mohamed Emam Sobeih
Session: Poster session 07
2188P - First-line combination of toripalimab and chemotherapy in advanced thymic carcinoma: A prospective, single-arm, phase II trial
Presenter: hui'yang shi
Session: Poster session 07
2189P - Combining SBRT with GM-CSF and Peg-IFNα to induce abscopal effects in previously treated patients with stage IV thymic tumors
Presenter: Boyan Wang
Session: Poster session 07
2190P - First-line atezolizumab in combination with platinum etoposide in patients with metastatic lung large cell neuroendocrine carcinoma (LCNEC)
Presenter: Georgios Evangelou
Session: Poster session 07
2191P - Real-world outcomes of patients with malignant pleural mesothelioma (MPM) treated with combination nivolumab and ipilimumab in the first- or later line setting
Presenter: Sabine Schmid
Session: Poster session 07
2192P - Quality of life (QoL) of patients (pts) with advanced malignant pleural mesothelioma (aMPM) treated in a real-world setting
Presenter: Abhenil Mittal
Session: Poster session 07
2193P - Real-world evidence of the impact of immunotherapy (IT) on overall survival (OS) of patients (p) with malignant pleural mesothelioma (MPM) adjusted for tumor histology
Presenter: Susana Cedres Perez
Session: Poster session 07